SARS-CoV-2 vaccination response in patients with haematological disease - CoVvhaem

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 160 人开始时间: 待定最近更新: 2024年4月9日

试验速览

Trial is onging in other countries

•all of the following
•* Currently treated, previously treated and non-treated patients
•diagnosed with the hematological malignancy multiple myeloma (including MGUS)
•chronic lymphocytic leukemia and non-Hodgkin lymphoma.
•Previously treated patient; is defined as: treatment <; 6 months before
•vaccination in patients that obtained a complete remission. Exceptions (no time
•restriction for last treatment) are patients with palliative treatment for
•ongoing haematological malignancies and patients after autologous and
•allogeneic stem cell transplantation.
•* Patients who are scheduled for and will undergo SARS-CoV-2
•vaccination.
•* Aged * 18 years.
•* Written informed consent.
•* Inclusion is irrespective of previously proven or possible (based on
•symptoms) COVID-19

•excluded from participation in this study:
•* Patients previously vaccinated for SARS-CoV-2.
•* Patients who have senile dementia, mental impairment or any other psychiatric
•disorder that prohibits the patient from understanding and giving informed
•* Any psychological, familial, sociological or geographical condition
•potentially hampering compliance with the study protocol.

发起方

Medisch Universitair Ziekenhuis Maastricht